Compare functional outcomes and treatment-related regret over 10 years in Spanish- and English-speaking Hispanic men compared to non-Hispanic men following treatment of localized prostate cancer.
Data from a prospective cohort study of men with localized prostate cancer treated with active surveillance, radical prostatectomy or radiotherapy were used to examine the effect of survey language (Spanish speaking vs. English speaking) and ethnicity (Hispanic vs. non-Hispanic) on functional outcomes and treatment-related regret over 10 years. Outcomes were measured using validated questionaries adjusting for baseline patient and disease characteristics.
A total of 770 men were included, 12% were Spanish-speaking and 12% were English-speaking Hispanic men. Compared to non-Hispanic men, Spanish-speaking Hispanic men had clinically meaningfully better urinary incontinence scores at years 3, 5 and 10 (adjusted mean difference [aMD], 12.4, 95% CI, 4.8 to 20.0; at year 10), as well as better bowel function scores at 10 years (aMD, 5.1, 95% CI 2.3 to 8.0). English-speaking Hispanic men had clinically worse urinary incontinence at 3 and 5 years (aMD, -10.7 [95% CI, -17.6 to -3.9]; at year 5) and bowel function at 10 years (aMD, -4.3 [95% CI, -8.2 to -0.4]) compared to Spanish-speaking Hispanic men. English-speaking Hispanic men were more likely to report regret than Spanish-speaking Hispanic men at 10 years (adjusted odds ratio, 7.9, 95% CI, 1.3-46.2).
These findings underscore the importance of considering language and ethnicity when providing counseling and support for prostate cancer survivors, emphasizing the need for personalized patient-centered care.
Urologic oncology. 2024 Dec 16 [Epub ahead of print]
Andrea A Lopez, Bashir Al Hussein Al Awamlh, Li-Ching Huang, Zhiguo Zhao, Tatsuki Koyama, Karen E Hoffman, Christopher J D Wallis, Kerri Cavanaugh, Ruchika Talwar, Alicia K Morgans, Michael Goodman, Ann S Hamilton, Xiao-Cheng Wu, Jie Li, Brock B O'Neil, David F Penson, Daniel A Barocas
Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, TN, USA., Department of Urology, Weill Cornell Medicine/NewYork-Presbyterian, New York, New York, USA., Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Department of Radiation Oncology, The University of Texas MD Anderson Center, Houston,Texas, USA., Division of Urology, Department of Surgery, University of Toronto; Mount Sinai Hospital; Department of Surgical Oncology, University Health Network, Toronto, Ontario, Canada., Division of Nephrology and Hypertension, Vanderbilt University Medical Center; Vanderbilt Center for Effective Health Communication, Nashville, TN, USA., Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA., Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia, USA., Department of Population and Public Health Sciences, Keck School of Medicine at the University of Southern California, Los Angeles, California, USA., Department of Epidemiology, Louisiana State University New Orleans School of Public Health, Baton Rouge, Lousiana, USA., Cancer Epidemiology Services, New Jersey Department of Health, Rutgers Cancer Institute of New Jersey and Rutgers School of Public Health, New Brunswick, New Jersey, USA., Department of Urology, University of Utah Health, Salt Lake City, Utah, USA., Department of Urology, Vanderbilt University Medical Center; Veterans Affairs Tennessee Valley Geriatric Research Education and Clinical Center, Nashville TN, USA., Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: .